2025-05-05 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0. Summary Statistics:**

JNJ, Johnson & Johnson, is a multinational healthcare corporation.  The following analysis examines its performance against the S&P 500 (VOO) based on provided data.


**1. Performance Comparison with S&P 500:**

* **JNJ Cumulative Return:** 37.66%
* **VOO (S&P 500) Cumulative Return:** 82.57%
* **Return Difference:** -44.9%
* **Relative Lag:** 32.8% (This means JNJ's underperformance relative to VOO falls within the 32.8th percentile of its historical range of under/outperformance).

The provided data shows that JNJ has significantly underperformed the S&P 500 over the analyzed period.  While the absolute underperformance is substantial, the relative lag puts this performance in context of its historical volatility against the S&P 500.


**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 33.0% | 55.5% | 1.0% | 0.1 | 274.9 |
| 2016-2018  | 15.0% | 10.7% | -6.0% | -0.0 | 260.8 |
| 2017-2019  | 25.0% | 10.7% | -8.0% | 0.7 | 303.1 |
| 2018-2020  | 20.0% | 59.4% | -10.0% | 0.5 | 335.9 |
| 2019-2021  | 35.0% | 59.5% | -25.0% | 0.4 | 374.3 |
| 2020-2022  | 8.0% | 61.3% | -1.0% | 0.3 | 396.7 |
| 2021-2023  | -17.0% | 61.3% | -38.0% | 0.4 | 362.6 |
| 2022-2024  | -31.0% | 61.3% | -51.0% | 0.3 | 345.2 |
| 2023-2025  | -1.0% | 69.7% | 0.1 | 0.1 | 372.8 |

The alpha values fluctuate considerably across years, indicating inconsistent outperformance against the market.  The beta is generally low, suggesting lower volatility than the market, though this has not translated into consistent positive alpha.


**2. Recent Price Movement:**

* **Closing Price:** $154.93
* **Last Market Price:** $156.12
* **5-Day Moving Average:** $156.49
* **20-Day Moving Average:** $155.535
* **60-Day Moving Average:** $158.4752

The price is slightly below the 5-day and 20-day moving averages, and notably below the 60-day moving average, suggesting a recent downward trend. The last market price shows a slight increase compared to the previous close, indicating a small positive daily movement.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **RSI:** 41.12 (Slightly below neutral; suggests potential for further downside)
* **PPO:** 0.2659 (Positive, but relatively low; suggests weak momentum)
* **Relative Strength Change (20-day):** -8.2% (Short-term bearish trend)
* **Expected Return (2+ years):** -53.6% (Significant underperformance compared to S&P 500 is anticipated for long-term investment.)

The indicators suggest a relatively bearish outlook for JNJ in the short term. The negative expected return highlights the significant underperformance against the S&P 500 anticipated over the long term.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2025-04-23 | 4.57 | $21.89B       |
| 2024-10-23 | 1.12 | $22.47B       |
| 2024-07-25 | 1.95 | $22.45B       |
| 2024-05-01 | 1.35 | $21.38B       |
| 2025-04-23 | 1.35 | $21.38B       |

Note: There's a duplicated entry for 2025-04-23.  Assuming this is an error, the earnings show significant variability.  Further analysis requires clarification on the duplication and a longer history of earnings data.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2025-03-31 | $21.89B  | 66.40%       |
| 2024-12-31 | $22.52B  | 68.35%       |
| 2024-09-30 | $22.47B  | 69.01%       |
| 2024-06-30 | $22.45B  | 69.40%       |
| 2024-03-31 | $21.38B  | 69.55%       |

Revenue is relatively stable, with profit margins consistently high but showing a slight downward trend.

**Capital and Profitability:**

| Quarter | Equity    | ROE      |
|---------|-----------|----------|
| 2025-03-31 | $78.11B  | 14.08%   |
| 2024-12-31 | $71.49B  | 4.80%    |
| 2024-09-30 | $70.16B  | 3.84%    |
| 2024-06-30 | $71.54B  | 6.55%    |
| 2024-03-31 | $70.02B  | 4.65%    |

Equity and ROE fluctuate, indicating variability in profitability.  The high ROE in 2025-03-31 needs further investigation to determine its sustainability.


**6. Overall Analysis:**

JNJ has shown significant underperformance against the S&P 500 over the analyzed period, with a substantial negative alpha and a relatively low beta. Technical indicators suggest a bearish short-term outlook, and the long-term expected return is significantly negative compared to the market benchmark. While the company maintains high profit margins and relatively stable revenue, the variability in earnings and ROE warrants further investigation.  The significant negative expected return and the inconsistent performance against the market raise serious concerns about the investment prospects of JNJ at this time.  Further due diligence, including a deeper dive into the company's fundamentals and future prospects, is strongly recommended before making any investment decisions.
